Surfagon | CAS#52435-06-0 | potent LHRH agonist

MedKoo Cat#: 598802 | Name: Surfagon

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Surfagon is a potent LHRH agonist.

Chemical Structure

Surfagon

CAS#52435-06-0

Theoretical Analysis

MedKoo Cat#: 598802

Name: Surfagon

CAS#: 52435-06-0

Chemical Formula: C56H78N16O12

Exact Mass: 1166.5985

Molecular Weight: 1167.34

Elemental Analysis: C, 57.62; H, 6.74; N, 19.20; O, 16.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Surfagon; AY-25,205; AY 25,205; AY25,205; LHRH-A2; TAP 127; WY 18481; WY-18481; WY18481; Dalarelin;

IUPAC/Chemical Name

(S)-N-ethyl-1-(((R)-5-oxopyrrolidine-2-carbonyl)-L-histidyl-L-tryptophyl-D-seryl-L-tyrosyl-D-alanyl-L-leucyl-L-arginyl)pyrrolidine-2-carboxamide

InChi Key

QLGKMLRGKPKGKI-MUVLZESKSA-N

InChi Code

1S/C56H78N16O12/c1-5-60-54(83)45-13-9-21-72(45)55(84)39(12-8-20-61-56(57)58)66-50(79)40(22-30(2)3)67-47(76)31(4)64-49(78)41(23-32-14-16-35(74)17-15-32)68-53(82)44(28-73)71-51(80)42(24-33-26-62-37-11-7-6-10-36(33)37)69-52(81)43(25-34-27-59-29-63-34)70-48(77)38-18-19-46(75)65-38/h6-7,10-11,14-17,26-27,29-31,38-45,62,73-74H,5,8-9,12-13,18-25,28H2,1-4H3,(H,59,63)(H,60,83)(H,64,78)(H,65,75)(H,66,79)(H,67,76)(H,68,82)(H,69,81)(H,70,77)(H,71,80)(H4,57,58,61)/t31-,38?,39+,40+,41+,42+,43+,44?,45+/m1/s1

SMILES Code

O=C([C@@H](NC([C@@H]1NC(CC1)=O)=O)Cc2cnc[nH]2)N[C@H](C(N[C@H](CO)C(N[C@@H](Cc3ccc(O)cc3)C(N[C@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N4CCC[C@H]4C(NCC)=O)=O)=O)=O)=O)=O)=O)Cc5c[nH]c6c5cccc6

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,167.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Krivosheev OG, Nabatchikova NA, Pozdniakova GI, Siutkin EA, Vinogradov VA. [Biological activity of surfagon--a synthetic luliberin agonist]. Probl Endokrinol (Mosk). 1988 Nov-Dec;34(6):62-6. Russian. PubMed PMID: 3148928. 2: Goncharova ND, Belova EG, Gorlushkin VM. [Effects of chronic surfagon administration on secretion of luteinizing hormone and morphofunctional state of the testes in Papio hamadryas]. Probl Endokrinol (Mosk). 1992 Jan-Feb;38(1):55-8. Russian. PubMed PMID: 1308599. 3: Krivosheev OG, Chernykh VIa, Vinogradov VA, Nabatchikova NA, Siutkin EA. [The experimental use of surfagon, a synthetic analog of luliberin, in follicular ovarian cysts]. Probl Endokrinol (Mosk). 1989 Nov-Dec;35(6):54-8. Russian. PubMed PMID: 2695918. 4: Sever'ianova LA, Bobyntsev II. [Effect of a luliberine analogue (surfagon) on food conditioning in rats with different sensitivity to ethanol]. Ross Fiziol Zh Im I M Sechenova. 1997 Mar;83(3):100-6. Russian. PubMed PMID: 12436689. 5: Smirnova IO, Balueva IM, Kiselev VI, Pavlova OM, Titov MI, Burenin IS. [Experimental approaches to treatment of prostatic adenoma with the luliberin analog surfagon]. Probl Endokrinol (Mosk). 1992 Jan-Feb;38(1):52-4. Russian. PubMed PMID: 1284993. 6: Bobyntsev II, Dolzhikov AA, Severyanova LA. Morphological changes in immune and endocrine organs of mice injected with a gonadotropin-releasing hormone analog. Bull Exp Biol Med. 2005 Jan;139(1):101-4. PubMed PMID: 16142290. 7: Krivosheev OG, Nabatchikova NA, Pozdnyakova GI, Syutkin EA, Vinogradov VA, Chernykh VYa, Veselova SP, Saks TR, Meertsuk FE. Biological activity of surfagon--a synthetic luliberin agonist. Neurosci Behav Physiol. 1989 Jul-Aug;19(4):341-5. PubMed PMID: 2510052. 8: Bobyntsev II, Dolzhikov AA, Sever'yanova LA. Morphological changes in immune and endocrine organs of stressed mice after administration of a gonadotropin-releasing hormone analogue. Bull Exp Biol Med. 2007 Nov;144(5):744-7. PubMed PMID: 18683513. 9: Bobyntsev II, Sever'yanova LA. Immunotropic effects of gonadotropin-releasing hormone analog under conditions of emotional painful stress. Bull Exp Biol Med. 2002 May;133(5):436-8. PubMed PMID: 12420053. 10: Sever'ianova LA, Bobyntsev II. [The effect of a luliberin analog on the formation of alcoholic motivation in rats]. Fiziol Zh Im I M Sechenova. 1993 Dec;79(12):23-7. Russian. PubMed PMID: 8162116. 11: Bobyntsev II, Sever'ianova LA, Liashev IuD. [Neurotropic effects of luliberin analog in rats with different sensitivity to ethanol]. Biull Eksp Biol Med. 1991 Dec;112(12):612-5. Russian. PubMed PMID: 1777627. 12: Goncharova ND, Mkhitarova LA, Gogiladze EM. [Regeneration of the function of the hypophyseal-gonadal system after its prolonged suppression with luliberin agonists]. Probl Endokrinol (Mosk). 1991 May-Jun;37(3):45-8. Russian. PubMed PMID: 1658774. 13: Bobyntsev II, Sever'ianova LA, Smakhtin MIu, Ktiukov AA. [Effect of the intraventricular administration of gonadotropin-releasing hormone analogue on immune response and unspecific resistance in rats]. Ross Fiziol Zh Im I M Sechenova. 2005 Oct;91(10):1176-81. Russian. PubMed PMID: 16335425. 14: Goncharova ND, Mkhitarova LA. [Hormonal function of the adrenal cortex in "medical castration" induced by prolonged infusion of luliberin agonists]. Probl Endokrinol (Mosk). 1993 Jan-Feb;39(1):51-4. Russian. PubMed PMID: 8058666. 15: Targońska K, Kucharczyk D. The application of hCG, CPH and Ovopel in successful artificial reproduction of goldfish (Carassius auratus auratus) under controlled conditions. Reprod Domest Anim. 2011 Aug;46(4):651-5. doi: 10.1111/j.1439-0531.2010.01723.x. Epub 2010 Dec 6. PubMed PMID: 21134006. 16: Bobyntsev II, Sever'ianova LA, Konoplia AI, Smakhtin MIu, Kriukov AA. [The effect of the synthetic analogue of gonadoliberin on immune response and factors of nonspecific resistance in rats and mice]. Ross Fiziol Zh Im I M Sechenova. 2002 Sep;88(9):1177-81. Russian. PubMed PMID: 12503425. 17: Sachyns'ka OV. [Nucleic acid and protein content in rat prostate during combined treatment with the gonadorelin agonist and an androgen receptor inhibitor]. Fiziol Zh. 2001;47(6):30-4. Ukrainian. PubMed PMID: 11962088. 18: Su ZH. [The value of the intravenous LRH stimulation test in the diagnosis of male hypogonadotropic hypogonadism]. Zhonghua Yi Xue Za Zhi. 1985 Nov;65(11):684-8. Chinese. PubMed PMID: 3938318. 19: Bobyntsev II, Sever'yanova LA, Kryukov AA. Effect of gonadotropin-releasing hormone analogue on thermal nociception in mice. Bull Exp Biol Med. 2006 Feb;141(2):193-6. PubMed PMID: 16984094. 20: Labrie F, Cusan L, Séguin C, Bélanger A, Pelletier G, Reeves J, Kelly PA, Lemay A, Raynaud JP. Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. Int J Fertil. 1980;25(3):157-70. PubMed PMID: 6108924.